|
gptkbp:instanceOf
|
gptkb:acetylcholinesterase_inhibitor
alkaloid
|
|
gptkbp:antidote
|
atropine poisoning
scopolamine poisoning
|
|
gptkbp:ATCCode
|
gptkb:N07AA03
|
|
gptkbp:CASNumber
|
57-47-6
|
|
gptkbp:category
|
gptkb:Dragon
alkaloid
antidote
cholinesterase inhibitor
carbamate
ophthalmology drug
|
|
gptkbp:chemicalFormula
|
C15H21N3O2
|
|
gptkbp:contraindication
|
asthma
cardiac conduction disturbances
|
|
gptkbp:crossesBloodBrainBarrier
|
yes
|
|
gptkbp:discoveredBy
|
gptkb:Jobst_and_Hesse
gptkb:Thomas_Richard_Fraser
|
|
gptkbp:discoveredIn
|
1864
|
|
gptkbp:eliminationHalfLife
|
15–40 minutes
|
|
gptkbp:firstIsolatedFrom
|
gptkb:Physostigma_venenosum
|
|
gptkbp:foundIn
|
gptkb:Calabar_bean
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Physostigmine
|
|
gptkbp:IUPACName
|
gptkb:(3aS,8aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl_N-methylcarbamate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
reversible inhibitor of acetylcholinesterase
|
|
gptkbp:meltingPoint
|
105–106 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
275.35 g/mol
|
|
gptkbp:origin
|
natural product
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL418
gptkb:DB00981
5983
|
|
gptkbp:relatedTo
|
gptkb:neostigmine
gptkb:pyridostigmine
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
seizures
bradycardia
asystole
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:synonym
|
gptkb:eserine
|
|
gptkbp:toxicity
|
yes
|
|
gptkbp:UNII
|
6QX9Q35T0J
|
|
gptkbp:usedFor
|
treatment of glaucoma
antidote for anticholinergic toxicity
|
|
gptkbp:bfsParent
|
gptkb:Antidotes
gptkb:Antidote
|
|
gptkbp:bfsLayer
|
5
|